tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VNDA Stock Latest News

Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley
The FlyVanda Pharmaceuticals price target raised to $17 from $14 at B. Riley
46m ago
VNDA
Vanda announces FDA accepted BLA for imsidolimab
PremiumThe Fly
Vanda announces FDA accepted BLA for imsidolimab
2h ago
VNDA
Midday Fly By: Trump ups worldwide tariff to 15%, Gilead buying Arcellx
PremiumThe Fly
Midday Fly By: Trump ups worldwide tariff to 15%, Gilead buying Arcellx
2d ago
D
DE
Unusually active option classes on open February 23rd
PremiumThe Fly
Unusually active option classes on open February 23rd
2d ago
FRO
SLS
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
2d ago
LYG
OWL
Vanda Wins FDA Approval for Bysanti Antipsychotic Therapy
PremiumCompany AnnouncementsVanda Wins FDA Approval for Bysanti Antipsychotic Therapy
2d ago
8K
VNDA
Vanda Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright
Premium
The Fly
Vanda Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright
2d ago
VNDA
Vanda trading resumes
Premium
The Fly
Vanda trading resumes
5d ago
VNDA
Vanda Pharmaceuticals announces FDA approval of Bysanti tablets
PremiumThe Fly
Vanda Pharmaceuticals announces FDA approval of Bysanti tablets
5d ago
VNDA
Vanda trading halted, news pending
PremiumThe Fly
Vanda trading halted, news pending
5d ago
VNDA
Vanda Board Approves 2025 Bonuses and 2026 Compensation
PremiumCompany Announcements
Vanda Board Approves 2025 Bonuses and 2026 Compensation
6d ago
8K
VNDA
FDA Calendar: Vanda Stock (VNDA) Shows 125% Upside with Bysanti Decision on Deck
PremiumMarket News
FDA Calendar: Vanda Stock (VNDA) Shows 125% Upside with Bysanti Decision on Deck
6d ago
VNDA
Regulatory Hurdles Cloud Vanda Pharmaceuticals’ Prospects for Bysanti and Imsidolimab FDA Approvals
PremiumCompany AnnouncementsRegulatory Hurdles Cloud Vanda Pharmaceuticals’ Prospects for Bysanti and Imsidolimab FDA Approvals
12d ago
VNDA
Vanda Pharmaceuticals Balances Growth With Rising Risks
Premium
Company Announcements
Vanda Pharmaceuticals Balances Growth With Rising Risks
13d ago
VNDA
Vanda Pharmaceuticals files $200M mixed securities shelf
Premium
The Fly
Vanda Pharmaceuticals files $200M mixed securities shelf
13d ago
VNDA
Vanda Pharmaceuticals reports Q4 EPS ($2.39) vs. (8c) last year
PremiumThe Fly
Vanda Pharmaceuticals reports Q4 EPS ($2.39) vs. (8c) last year
14d ago
VNDA
Vanda Pharmaceuticals sees FY26 revenue $230M-$260M, consensus $271.27M
PremiumThe Fly
Vanda Pharmaceuticals sees FY26 revenue $230M-$260M, consensus $271.27M
14d ago
VNDA
VNDA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
VNDA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
16d ago
VNDA
Vanda Pharmaceuticals Advances Ponesimod Into Phase 3 Psoriasis Study: What Investors Should Know
PremiumCompany Announcements
Vanda Pharmaceuticals Advances Ponesimod Into Phase 3 Psoriasis Study: What Investors Should Know
1M ago
VNDA
Maintaining Buy Rating on Vanda: Limited Impact from Tasimelteon Setback, Ongoing FDA Engagement, and Bysanti Catalyst Support $22 Target
PremiumRatingsMaintaining Buy Rating on Vanda: Limited Impact from Tasimelteon Setback, Ongoing FDA Engagement, and Bysanti Catalyst Support $22 Target
2M ago
VNDA
H.C. Wainwright says rejection of Vanda’s tasimelteon ‘only minor setback’
Premium
The Fly
H.C. Wainwright says rejection of Vanda’s tasimelteon ‘only minor setback’
2M ago
VNDA
Vanda Faces FDA Setback on HETLIOZ Jet Lag Application
Premium
Company Announcements
Vanda Faces FDA Setback on HETLIOZ Jet Lag Application
2M ago
8K
VNDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >